News
TRDA
6.87
-2.69%
-0.19
Entrada Q2 Loss Shrinks; Data From Phase 1/2 Trials In DMD And DM1 Expected In '27
NASDAQ · 3d ago
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA)
TipRanks · 4d ago
Entrada Therapeutics reports Q2 results
Seeking Alpha · 4d ago
Press Release: Entrada Therapeutics Reports -2-
Dow Jones · 5d ago
Big Insider Moves Rock Entrada Therapeutics as Key Players Cut Their Stakes
TipRanks · 6d ago
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 08/03 12:05
Weekly Report: what happened at TRDA last week (0727-0731)?
Weekly Report · 08/03 09:16
Weekly Report: what happened at TRDA last week (0720-0724)?
Weekly Report · 07/27 09:17
Weekly Report: what happened at TRDA last week (0713-0717)?
Weekly Report · 07/20 09:16
Weekly Report: what happened at TRDA last week (0706-0710)?
Weekly Report · 07/13 09:16
Weekly Report: what happened at TRDA last week (0629-0703)?
Weekly Report · 07/06 09:17
Weekly Report: what happened at TRDA last week (0622-0626)?
Weekly Report · 06/29 09:16
Weekly Report: what happened at TRDA last week (0615-0619)?
Weekly Report · 06/22 09:18
Weekly Report: what happened at TRDA last week (0608-0612)?
Weekly Report · 06/15 09:18
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 06/10 21:05
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
TipRanks · 06/10 20:52
Entrada Therapeutics Price Target Cut to $17.00/Share From $20.00 by Guggenheim
Dow Jones · 06/08 14:28
Entrada Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 06/08 14:28
Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17
Benzinga · 06/08 14:18
Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim
TipRanks · 06/08 11:22
More
Webull provides a variety of real-time TRDA stock news. You can receive the latest news about Entrada Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.